In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genmab downgraded after HuMax-CD20 success brings "unneccesary" R&D cost rise

This article was originally published in Scrip

Executive Summary

Cannacord Adamsanalysts have revised their recommendation for Genmabfrom buy to hold, following the company's recent stock price appreciation attributed to positive HuMax-CD20 (ofatumumab) Phase III chronic lymphocytic leukaemia (CLL) results. The analysts said that while they recognise Genmab's recent clinical success and other positive news about the company this year, they still had concerns.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts